NCT01631071View on ClinicalTrials.gov

Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains

NACompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Influenza
Interventions
BIOLOGICAL

Virosomal influenza vaccine

Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine

Trial Locations (1)

6864

CROSS-Research SA, Arzo

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT01631071 - Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains | Biotech Hunter | Biotech Hunter